HER2-NEGATIVE BREAST CANCER
Clinical trials for HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill shows promise against tough breast cancer
Disease control CompletedThis study tested a new daily pill, OP-1250, in 153 adults with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. The goal was to find the right dose, check safety, and see if the drug can shrink tumors. Participants had already tried at least one hor…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
New Pre-Surgery drug combo shows promise in slowing breast cancer growth
Knowledge-focused CompletedThis study tested whether adding a drug that targets specific genetic changes in breast tumors before surgery can slow tumor growth better than standard hormone therapy alone. It involved 19 women with ER-positive, HER2-negative breast cancer. The approach aims to personalize tre…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Jennifer Lee Caswell-Jin • Aim: Knowledge-focused
Last updated May 26, 2026 06:08 UTC
-
New test may predict olaparib success in advanced breast cancer
Knowledge-focused CompletedThis study looked at 65 people with advanced HER2-negative breast cancer who have certain gene mutations. Researchers used a test called RAD51-foci to see if it could predict how well the drug olaparib would work. The goal was to find a better way to match patients with the right…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Knowledge-focused
Last updated May 20, 2026 11:55 UTC